IFFIm vaccine bonds to launch
The International Finance Facility for Immunization (IFFIm) is to launch its bonds to Japanese investors, following a successful debut in the UK which raised $1.0 billion in November 2006. The scheme involves raising cash for immediate use for immunization projects against future income from government aid subsidies.
Alan Gillespie, the IFFIm's chairman, said: "there is no value immunizing a child in 2015, when funds might become available, if that child is going to die of disease this year."
The funds will be raised via Daiwa Securities Group and used to support the work of the GAVI Alliance, the World Health Organizaton, national governments, the Bill and Melinda Gates Foundation and vaccine makers.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze